FDA grants Breakthrough Designation to Servier's Emiltatug Ledadotin for ACC

Key facts

• Servier's Emiltatug Ledadotin (Emi-Le) received FDA Breakthrough Designation.
• The designation is for treating locally advanced, recurrent, or metastatic ACC.
• Phase 1 data indicated Emi-Le was well tolerated.
• The drug was presented at ASCO 2026.

Adenoid Cystic Carcinoma (ACC) is a rare and aggressive cancer. The FDA's Breakthrough Designation is intended to expedite the development and review of drugs that treat serious conditions and demonstrate substantial improvement over available therapies. This designation for Emiltatug Ledadotin suggests potential for faster market access if further trials are successful.